Status:
COMPLETED
CD155 in Bladder Cancer
Lead Sponsor:
Fudan University
Conditions:
Bladder Cancer
Eligibility:
All Genders
18-85 years
Brief Summary
This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.
Eligibility Criteria
Inclusion
- patients with non-metastatic muscle invasive bladder cancer
- pathology confirmed urothelial carcinoma
- underwent cystectomy and pelvic lymph node dissection
Exclusion
- not enough tissue for immunohistochemistry
- patients with a second neoplasm
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT03789682
Start Date
January 1 2018
End Date
January 1 2025
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032